News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
SAFC (Sigma-Aldrich Corporation) says it will invest across its life science businesses following a first quarter that saw “weak” contract manufacturing but flourishing viral and cell media sectors.
A ‘spinning membrane’ technology could provide an automated solution to the manual problem of cell washing in both upstream and downstream processes says Fresenius Kabi.
Bristol-Myers Squibb and Samsung Biologics have expanded their existing agreement in which Samsung will manufacture several unnamed biologics at its Incheon, South Korea manufacturing site. Financial terms of the agreement were not disclosed.